전립선암에서 조직 내 Tubulin α와 βII 발현의 임상적 의의

초록

Purpose: This study examined the significance of tubulin α and β II expression in benign prostatic hyperplasia (BPH) and prostate cancer. Materials and Methods: A total 103 cases diagnosed with either BPH or prostate cancer were divided into 4 groups: BPH (n=25), localized prostate cancer (n=41), locally advanced prostate cancer (n=18), metastatic prostate cancer (n=18). The tissues were taken through a transurethral resection of the prostate, suprapubic prostatectomy, prostatic needle biopsy or radical retropubic prostatectomy. The expression was measured by immunohistochemical staining. The degree of expression was graded on a 4-point scale. The data was compared in terms of stage, the serum prostatic specific antigen (PSA) level and Gleason score. The statistical comparisons were made using one-way ANOVA test and a Fisher's exact test. Results: The levels of tubulin α and β II expression were stronger in the patients with prostate cancer than those with BPH (p < 0.001). On the other hand, there was no difference between metastatic prostate cancer and localized prostate cancer (p > 0.05). The level of tubulin α expression was stronger in the patients with a Gleason score ≥ 8 than in those of Gleason score ≤7 (p<0.05), but there was no such difference in tubulin β II expression. The level of tubulin α and β II expression was stronger in the patients with a serum PSA level ≥4ng/ml than in those with the serum PSA level <4ng/ml (p<0.001). Conclusions: The expression of tubulin α and β II may be associated with the development of prostate cancer. These might be used as useful markers for the diagnosis, prognosis and treatment response.

키워드